Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | HTT | P42858 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.79 |
| ▸ | TP53 | P04637 | 4/20 | 0.79 |
| ▸ | RAB9A | P51151 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690385 | 0.87 | HPGD (0.77) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL7678596 | 0.87 | LMNA (0.88) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL18330530 | 0.86 | LMNA (0.75) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL8812455 | 0.86 | LMNA (0.75) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL845142 | 0.85 | LMNA (1.00) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL8437615 | 0.83 | LMNA (0.71) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL11400333 | 0.83 | LMNA (1.00) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL28842312 | 0.83 | LMNA (0.96) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL28842439 | 0.83 | LMNA (0.96) | LMNAHTTHSD17B10HPGDKDM4E | |
| SCHEMBL11234468 | 0.82 | LMNA (0.69) | LMNAHTTHSD17B10HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534657-B1 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA TECH SARL (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | SHIONGI & CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1534657-A4 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA TECH SARL (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2006060082-A1 | TRICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE THEREOF AS CHOLINESTERASE ACTIVITY INHIBITORS | THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1534657-A1 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA Technologies S.à.r.l. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020381-A1 | PROCESS FOR PREPARING ALDEHYDE COMPOUNDS | INVISTA TECHNOLOGIES S.À.R.L. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-6664427-B1 | From an unsaturated compound by hydroformylation and in the presence of a catalyst system comprising a Group VIII metal and a bidentate phosphorus ligand having two trivalent phosphorus atoms bound to salicylanilide groups | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-4310682-A | FUNGICIDES, BACTERICIDES | NISSAN CHEMICAL INDUSTRES, LTD., A CORP. OF JAPAN (JP) | 1982-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | CCNY, HDGF, GLI1 | LMNA 2426/4885HTT 1899/4885HSD17B10 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.